Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Beginning Cash Balance (2021 - 2023)

Bioadaptives' Beginning Cash Balance history spans 3 years, with the latest figure at $50000.0 for Q3 2023.

  • Quarterly results put Beginning Cash Balance at $50000.0 for Q3 2023, changed N/A from a year ago — trailing twelve months through Dec 2024 was $50000.0 (changed 0.0% YoY), and the annual figure for FY2023 was $50000.0, up 2980.71%.
  • Beginning Cash Balance for Q3 2023 was $50000.0 at Bioadaptives, up from $1623.0 in the prior quarter.
  • In the past five years, Beginning Cash Balance ranged from a high of $50000.0 in Q3 2023 to a low of $1623.0 in Q1 2021.
  • The 3-year median for Beginning Cash Balance is $1623.0 (2021), against an average of $17748.7.
  • Peak annual rise in Beginning Cash Balance hit 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
  • Year by year, Beginning Cash Balance stood at $1623.0 in 2021, then changed by 0.0% to $1623.0 in 2022, then surged by 2980.71% to $50000.0 in 2023.
  • According to Business Quant data, Beginning Cash Balance over the past three periods came in at $50000.0, $1623.0, and $1623.0 for Q3 2023, Q1 2022, and Q1 2021 respectively.